Tamiflu Data Reassures FDA Panel; Label Changes To Stress Flu’s Role In AEs
Executive Summary
Despite the fact that safety questions linked to Roche's influenza drug Tamiflu (oseltamivir) are still lingering, the data on the drug presented by the firm to FDA's Pediatric Advisory Committee is proof that the "system worked," panelists said at the Nov. 27 meeting
You may also be interested in...
Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008
Roche spending increases on pharmaceutical research and development will continue to outpace sales gains in 2008, company executives said during the firm's fourth quarter financial review Jan. 30
Advertisements For Flu Treatments Reflect Pharma’s Shift Toward New Media
A combination of a weak flu season and a shift in marketing strategies has resulted in fewer traditional direct-to-consumer advertising campaigns in the past two years by the leading manufacturers of flu medications
Advertisements For Flu Treatments Reflect Pharma’s Shift Toward New Media
A combination of a weak flu season and a shift in marketing strategies has resulted in fewer traditional direct-to-consumer advertising campaigns in the past two years by the leading manufacturers of flu medications